WO2011099031A1 - Antioxydants actifs pour tous les groupes d'âge - Google Patents
Antioxydants actifs pour tous les groupes d'âge Download PDFInfo
- Publication number
- WO2011099031A1 WO2011099031A1 PCT/IN2010/000872 IN2010000872W WO2011099031A1 WO 2011099031 A1 WO2011099031 A1 WO 2011099031A1 IN 2010000872 W IN2010000872 W IN 2010000872W WO 2011099031 A1 WO2011099031 A1 WO 2011099031A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- folic acid
- dha
- recited
- epa
- folate
- Prior art date
Links
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 30
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 38
- 239000011724 folic acid Substances 0.000 claims abstract description 25
- 235000019152 folic acid Nutrition 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 229960000304 folic acid Drugs 0.000 claims abstract description 13
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940014144 folate Drugs 0.000 claims abstract description 10
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 9
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 9
- 235000012661 lycopene Nutrition 0.000 claims abstract description 9
- 229960004999 lycopene Drugs 0.000 claims abstract description 9
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 9
- 239000001751 lycopene Substances 0.000 claims abstract description 9
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims abstract description 7
- 108090000790 Enzymes Proteins 0.000 claims abstract description 7
- 230000008901 benefit Effects 0.000 claims abstract description 7
- 208000019622 heart disease Diseases 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims abstract description 5
- 239000008280 blood Substances 0.000 claims abstract description 5
- 235000005911 diet Nutrition 0.000 claims abstract description 5
- 230000000378 dietary effect Effects 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 4
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims abstract description 3
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims abstract description 3
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims abstract description 3
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims abstract description 3
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims abstract description 3
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims abstract description 3
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims abstract description 3
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims abstract description 3
- 241000282412 Homo Species 0.000 claims abstract description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 3
- 208000007502 anemia Diseases 0.000 claims abstract description 3
- 210000004556 brain Anatomy 0.000 claims abstract description 3
- 210000000481 breast Anatomy 0.000 claims abstract description 3
- 210000003679 cervix uteri Anatomy 0.000 claims abstract description 3
- 238000002512 chemotherapy Methods 0.000 claims abstract description 3
- 210000001072 colon Anatomy 0.000 claims abstract description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 3
- 230000036267 drug metabolism Effects 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims abstract description 3
- 150000002066 eicosanoids Chemical class 0.000 claims abstract description 3
- 210000003238 esophagus Anatomy 0.000 claims abstract description 3
- 229930195729 fatty acid Natural products 0.000 claims abstract description 3
- 239000000194 fatty acid Substances 0.000 claims abstract description 3
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 3
- 229940019142 folic acid 5 mg Drugs 0.000 claims abstract description 3
- 230000002440 hepatic effect Effects 0.000 claims abstract description 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 3
- 210000004072 lung Anatomy 0.000 claims abstract description 3
- 210000000214 mouth Anatomy 0.000 claims abstract description 3
- 210000000496 pancreas Anatomy 0.000 claims abstract description 3
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 3
- 210000002307 prostate Anatomy 0.000 claims abstract description 3
- 210000000664 rectum Anatomy 0.000 claims abstract description 3
- 230000004044 response Effects 0.000 claims abstract description 3
- 210000001525 retina Anatomy 0.000 claims abstract description 3
- 210000002784 stomach Anatomy 0.000 claims abstract description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 3
- 235000021068 Western diet Nutrition 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- 235000008429 bread Nutrition 0.000 claims abstract 2
- 230000032823 cell division Effects 0.000 claims abstract 2
- 230000010261 cell growth Effects 0.000 claims abstract 2
- 210000003743 erythrocyte Anatomy 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims abstract 2
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 2
- 235000013311 vegetables Nutrition 0.000 claims abstract 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 13
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 11
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims 1
- 229930003761 Vitamin B9 Natural products 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 235000019159 vitamin B9 Nutrition 0.000 abstract description 3
- 239000011727 vitamin B9 Substances 0.000 abstract description 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 235000020685 fortified cereal Nutrition 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 description 18
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010016880 Folate deficiency Diseases 0.000 description 4
- 229940088623 biologically active substance Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000009206 Abruptio Placentae Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 206010065604 Suicidal behaviour Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 150000002026 docosanoids Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000501 femur body Anatomy 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 108010088383 interleukin-6 receptor alpha Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000021032 oily fish Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000008532 placental abruption Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- 150000003535 tetraterpenes Chemical class 0.000 description 1
- 235000009657 tetraterpenes Nutrition 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Definitions
- FIELD OF INVENTION This invention is based on active antioxidants which are useful for all age group like adult, kids thereof.
- a method of providing controlled release of a biologically active substance within a subject's digestive system comprising administering a biologically active substance to a subject's digestive system.
- the biologically active substance is administered concurrently with one or more soluble fibers in an oral dosage unit.
- the soluble fibers interact with the biologically active substance within the subject's digestive system to moderate and control the release of the biologically active substances in the subject's bloodstream. This provides more constant blood concentrations of the biologically active substances.
- the amount of soluble fibers in the oral dosage unit is greater than 40% by weight, and in some cases greater than 50% by weight of the oral dosage unit.
- the oral dosage unit typically contains from about 1 to 15g of soluble fiber, and in some cases from about 3 to 5g of soluble fiber.
- the biologically active substance may contain phytonutrients that promote the subject's cardiovascular system, immune system, or weight management.
- the main object of the invention is to provide an active antioxidant for the all age group.
- Prior antioxidants targeted on the particular age group. This is one of the strong antioxidant as comparative to others. Deficiency of antioxidants or low level of the same can cause oxidative stress and hence eventually kill cells. For all this reasons antioxidants are so important for the body metabolism and it also helps in lowering down the cell aging.
- STATEMENT OF INVENTION This invention is based on active antioxidants which are useful for all age group like adult, kids thereof. These are active antioxidants. They work on whole body as well as its metabolism.
- This invention is based on the strong antioxidants which are essential for all age group.
- Oxidation is a chemical reaction that transfers electrons from a substance to an oxidizing agent. Oxidation reactions can produce free radicals, which start chain reactions that damage cells. Antioxidants terminate these chain reactions by removing free radical intermediates, and inhibit other oxidation reactions by being oxidized themselves. As a result, antioxidants are often reducing agents such as thiols, ascorbic acid or polyphenols. Antioxidants are also widely used as ingredients in dietary supplements in the hope of maintaining health and preventing diseases such as cancer and coronary heart disease. Although initial studies suggested that antioxidant supplements might promote health, later large clinical trials did not detect any benefit and suggested instead that excess supplementation may be harmful.
- antioxidants In addition to the uses of natural antioxidants in medicine, oxidation reactions are crucial for life, they can also be damaging; hence, plants and animals maintain complex systems of multiple types of antioxidants, such as glutathione, vitamin C, and vitamin E as well as enzymes such as catalase, superoxide dismutase and various peroxidases.
- EPA Eicosapentaenoic acid (EPA or also icosapentaenoic acid) is an omega-3 fatty acid. EPA and its metabolites act in the body largely by their interactions with the metabolites of arachidonic acid; It is obtained in the human diet by eating oily fish or fish oil— cod liver, herring, mackerel, salmon, menhaden and sardine. It is also found in human milk. It's beneficial potential in mental conditions, such as schizophrenia.. EPA may affect depression, and importantly, suicidal behavior. EPA has inhibitory effect on CYP2C9 and CYP2C19 hepatic enzymes.
- DHA Docosahexaenoic acid is an omega-3 fatty acid. DHA is metabolized to form the docosanoids, which comprise several families of potent hormones. DHA is a major fatty acid in sperm and brain phospholipids, particularly in the retina. Dietary DHA may reduce the risk of heart disease by reducing the level of blood triglycerides in humans. Low levels of DHA have been associated with Alzheimer's disease.
- Folic acid also known as vitamin B9 or folacin
- folate the naturally occurring form
- pteroyl-L-glutamic acid and pteroyl-L-glutamate are forms of the water-soluble vitamin B9.
- Folic acid is itself not biologically active, but its biological importance is due to tetrahydrofolate and other derivatives after its conversion to dihydrofolic acid in the liver.
- Heart disease - Folic acid is a safe and effective supplement that targets large artery stiffness and may prevent isolated systolic hypertension, it may improve the integrity of the vascular endothelium.
- Bone loss in Parkinson's disease (PD)-Folate lowers homocysteine (Hey) levels which in turn prevents bone loss in Parkinson's disease (PD) patients taking levodopa (a psychoactive drug taken to treat Parkinson's disease). Improvements in bone health include increased BMD at the lumbar spine, total femur, and femur shaft.
- Schizophrenia-Folate deficiency may increase the risk of schizophrenia because by increasing homocysteine levels folate also increases interleukin 6 and tumor necrosis factor alpha levels and these two cytokines are involved in the development of schizophrenia.
- Renal disease-Folic acid supplements may reduce the risk of children developing renal diseases or injuries such as microalbuminuria.
- Lycopene It's a symmetrical tetraterpene assembled from 8 isoprene units. Their antioxidant property, substantial scientific and clinical research has been devoted to a possible correlation between lycopene consumption and general health. Early research suggested some amelioration of cardiovascular disease, cancer, diabetes, osteoporosis, and even male infertility. Lycopene helps neutralize harmful free radicals, which are implicated in cancer, heart disease, macular degeneration and other age-related illnesses. The evidence for a benefit was strongest for cancers of the prostate, lung, and stomach. Data were also suggestive of a benefit for cancers of the pancreas, colon and rectum, esophagus, oral cavity, breast, and cervix
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Cette invention concerne des antioxydants puissants, utiles pour tous les groupes d'âge. La composition basique est constituée des ingrédients suivants: EPA (150 mg), DHA (100 mg), acide folique (5 mg) et lycopène (50 mg). Le DHA est un acide gras principal présent dans le sperme, dans les phospholipides de cerveau, et en particulier dans la rétine. Le DHA diététique peut réduire le risque de maladie cardiaque par réduction du taux des triglycérides du sang chez les êtres humains. Le DHA a été associé, à de faibles niveaux, à la maladie d'Alzheimer. La vitamine B9 (acide folique et folate inclus) est essentielle pour de nombreuses fonctions organiques allant de la biosynthèse des nucléotides à la reméthylation de l'homocystéine. Le corps humain a besoin de folate pour synthétiser, réparer et méthyler l'ADN, ainsi que pour agir comme cofacteur dans des réactions biologiques faisant intervenir le folate. Il est particulièrement important en périodes de division cellulaire et de croissance rapide. Aussi bien les enfants que les adultes ont besoin d'acide folique pour produire des globules rouges sains et empêcher l'anémie. Le folate et l'acide folique tiennent leur nom du mot latin folium (qui signifie "feuille"). Les légumes-feuilles en sont une source principale, bien que dans les régimes alimentaires occidentaux, les céréales et le pain enrichis peuvent être une plus grande source alimentaire. L'EPA présente une action inhibitrice sur les enzymes hépatiques CYP2C9 et CYP2C19. À dose élevée, il peut également inhiber l'activité de CYP2D6 et CYP3A4, enzymes importantes intervenant dans le métabolisme d'un médicament. L'EPA améliore la réponse des patients à la chimiothérapie, éventuellement par modulation de la production des éicosanoïdes. Il pourrait également réduire le risque de développement de certains types de cancer, notamment le myélome multiple. Le lycopène contribue à neutraliser les radicaux libres nuisibles impliqués dans le cancer, la cardiopathie, la dégénérescence maculaire et autres maladies liées à l'âge. Les avantages ont été plus marqués s'agissant des cancers de la prostate, du poumon et de l'estomac. Des données ont été également suggéré concernant des avantages sur les cancers du pancréas, des côlon et rectum, de l'oesophage, de la cavité buccale, du sein, et du col de l'utérus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN373MU2010 | 2010-02-11 | ||
| IN373/MUM/2010 | 2010-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011099031A1 true WO2011099031A1 (fr) | 2011-08-18 |
Family
ID=44063945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2010/000872 WO2011099031A1 (fr) | 2010-02-11 | 2010-12-30 | Antioxydants actifs pour tous les groupes d'âge |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2011099031A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2759044C1 (ru) * | 2020-09-23 | 2021-11-09 | Федеральное государственное бюджетное учреждение "Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства" (ФГБУ РосНИИГТ ФМБА России) | Способ коррекции анемии в предоперационном периоде у больных раком желудка |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6649195B1 (en) | 2002-07-11 | 2003-11-18 | Vitacost.Com, Inc. | Eyesight enhanced maintenance composition |
| WO2007076416A2 (fr) * | 2005-12-20 | 2007-07-05 | Alcon Research, Ltd. | Composition et procedes d’inhibition de la progression d’une degeneration maculaire et promotion d’une vision saine |
| WO2009020595A2 (fr) * | 2007-08-03 | 2009-02-12 | Shaklee Corporation | Système de complément nutritionnel |
| DE202009002126U1 (de) * | 2009-02-13 | 2009-04-16 | Orthomol Pharmazeutische Vertriebs Gmbh | Spurenelement enthaltende Zusammensetzung |
| WO2009053824A1 (fr) | 2007-10-23 | 2009-04-30 | Laboratorio Chimico Internazionale S.P.A. | Composition de pastilles d'acide lipoïque |
| GB2458466A (en) * | 2008-03-18 | 2009-09-23 | Kartar Singh Lalvani | Composition for hair, skin and nail health maintenance |
-
2010
- 2010-12-30 WO PCT/IN2010/000872 patent/WO2011099031A1/fr active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6649195B1 (en) | 2002-07-11 | 2003-11-18 | Vitacost.Com, Inc. | Eyesight enhanced maintenance composition |
| WO2007076416A2 (fr) * | 2005-12-20 | 2007-07-05 | Alcon Research, Ltd. | Composition et procedes d’inhibition de la progression d’une degeneration maculaire et promotion d’une vision saine |
| WO2009020595A2 (fr) * | 2007-08-03 | 2009-02-12 | Shaklee Corporation | Système de complément nutritionnel |
| WO2009053824A1 (fr) | 2007-10-23 | 2009-04-30 | Laboratorio Chimico Internazionale S.P.A. | Composition de pastilles d'acide lipoïque |
| GB2458466A (en) * | 2008-03-18 | 2009-09-23 | Kartar Singh Lalvani | Composition for hair, skin and nail health maintenance |
| DE202009002126U1 (de) * | 2009-02-13 | 2009-04-16 | Orthomol Pharmazeutische Vertriebs Gmbh | Spurenelement enthaltende Zusammensetzung |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2759044C1 (ru) * | 2020-09-23 | 2021-11-09 | Федеральное государственное бюджетное учреждение "Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства" (ФГБУ РосНИИГТ ФМБА России) | Способ коррекции анемии в предоперационном периоде у больных раком желудка |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20020025088A (ko) | 필수지방산 및 호모시스테인-저하제를 포함하는 약제학적및 영양학적 조성물 | |
| DK2389077T3 (en) | Nutritional supplements for individuals 50+ to improve vitality, immunity and health of the eyes and bones | |
| JP2008501686A (ja) | 栄養製剤 | |
| JP7336994B2 (ja) | 温熱療法治療を増強するための組成物および方法 | |
| US20130101569A1 (en) | Hair growth stimulant | |
| US20210315852A1 (en) | Delivery methods for omega-3's and compositions for vitamins and minerals used to enhance visual acuity and mental development in the human body | |
| WO2001056572A1 (fr) | Compositions et methodes destinees a favoriser l'entretien d'articulations saines | |
| US20240325337A1 (en) | Tetrahydrocurcuminoid-metal complexes, manufacturing methods thereof, and uses thereof | |
| WO2008059965A1 (fr) | Agent pour soulager ou prévenir des symptômes de stress et agent pour améliorer des états mentaux | |
| Prasad | Antioxidants in cancer care: when and how to use them as an adjunct to standard and experimental therapies | |
| JP2015007092A (ja) | 大量の栄養補給剤の負の副作用なしに、環境ストレスの作用に対抗し、免疫を改善し、活動力を改善し、一方でビタミンおよび無機質の欠乏に対処するための、マルチビタミン／無機質配合物 | |
| CN101631542B (zh) | 神经再生剂 | |
| WO2013013979A1 (fr) | Utilisation de citrulline et association médicamenteuse pour améliorer la fécondité masculine | |
| US20130064924A1 (en) | Nutritional supplement for use under physiologically stressful conditions | |
| US8557236B2 (en) | Cardiovascular support supplement and compositions and methods thereof | |
| WO2011099031A1 (fr) | Antioxydants actifs pour tous les groupes d'âge | |
| AT510810A1 (de) | Kombinationspräparat zur verbesserung der weiblichen fertilität | |
| WO2015069974A1 (fr) | Capsules contenant des préparations de compléments alimentaires à absorption accrue de nutriments lipophiles | |
| JP2024517556A (ja) | コエンザイムｑ１０含有液状補助飼料組成物 | |
| US11116246B2 (en) | Compositions of coenzyme Q10 and methods of use | |
| Prasad | Fight heart disease with vitamins and antioxidants | |
| Van Schoor | Vitamin and mineral supplements |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10824283 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 10824283 Country of ref document: EP Kind code of ref document: A1 |